Cardiol Therapeutics (TSX:CRDL) 3-Year Book Growth Rate : 2.30% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics 3-Year Book Growth Rate?

Cardiol Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was C$0.43.

During the past 12 months, Cardiol Therapeutics's average Book Value per Share Growth Rate was -47.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was 2.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Cardiol Therapeutics was 47.50% per year. The lowest was 2.30% per year. And the median was 10.40% per year.

Competitive Comparison of Cardiol Therapeutics's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's 3-Year Book Growth Rate falls into.

Cardiol Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Cardiol Therapeutics (TSX:CRDL) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Cardiol Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre

Senior Officer